Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $60.00 price target on the stock.
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15 [Yahoo! Finance]
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)